IMMX NXC-201 AL Amyloidosis: 95% CR at $592M

AL amyloidosis is a rare plasma cell disorder with an incidence of approximately 10 per million people. The immune system produces toxic light chains that clog the heart, kidneys, and liver, causing organ failure and death. There are zero FDA-approved CAR-T therapies for this indication. Immix Biopharma (IMMX) is trying to be first.

At $8.32 per share, IMMX carries a $592 million market cap, has 21 employees, zero revenue, and one asset: NXC-201, an autologous BCMA-directed CAR-T cell therapy. The NEXICART-2 trial (NCT06097832) has completed enrollment of 45 patients. Top-line results are expected in Q3 2026, with the next interim update expected in late September 2026. This is a binary readout at a micro-cap. Position sizing is everything.

The NEXICART-2 data so far

NEXICART-2 is a single-arm, multi-site U.S. Phase 2 trial with a registrational design. The trial enrolled 45 patients with relapsed or refractory AL amyloidosis after prior lines of therapy. The primary endpoint is complete response (CR) rate by independent review committee.

The data has improved with each update. At ASH 2025 (December 7, 2025), the company reported a CR rate of 75% (15 of 20 patients) at the s/u IFE-negative level. By the May 21, 2026 interim update, the CR rate had climbed to 95% (19 of the first 20 evaluable patients in the updated cohort). The company also reported that no neurotoxicity was observed in the Phase 2 study, and only low-grade cytokine release syndrome (CRS) was reported, with a median duration short enough that NXC-201 has been called a potential “single-day CRS” CAR-T.

The FDA granted Breakthrough Therapy Designation to NXC-201 for relapsed or refractory AL amyloidosis on January 28, 2026, based on the ASH 2025 interim data. The therapy also holds RMAT designation and Orphan Drug Designation from both the FDA and EMA.

Autologous, not allogeneic

The brief that generated this analysis described NXC-201 as an allogeneic CAR-T. That is factually incorrect. NXC-201 is an autologous BCMA-targeted CAR-T cell therapy. The patient’s own T cells are extracted, engineered to express a chimeric antigen receptor targeting BCMA on the malignant plasma cells that drive AL amyloidosis, and reinfused. This is the same manufacturing model as Gilead’s BCMA CAR-T programs and Carvykti.

NXC-201 incorporates a proprietary “digital filter” designed to filter out non-specific T-cell activation, which the company claims reduces CRS and neurotoxicity. The safety data supports that claim so far: zero neurotoxicity and only low-grade CRS in the Phase 2 cohort.

The autologous distinction matters for the investment thesis. Autologous CAR-T manufacturing is proven but expensive and slow, with vein-to-vein times of 3 to 6 weeks. For allogeneic cell therapy, the promise is off-the-shelf dosing at lower cost, but durability and persistence remain unresolved problems. IMMX is not promising to solve the manufacturing bottleneck. It is promising to be the first autologous CAR-T approved in a disease with zero CAR-T competition.

Market sizing and the comp

AL amyloidosis develops in up to 15% of multiple myeloma patients. The AL amyloidosis treatment market was valued at approximately $4 billion in 2026 and is projected to reach $6.38 billion by 2030 at a 12.6% CAGR. There are approximately 38,500 US patients.

NXC-201 is priced at approximately $400,000 per dose in analyst models, in line with existing BCMA CAR-T pricing. Carvykti (cilta-cel), the Janssen/Legend Biologics BCMA CAR-T for multiple myeloma, generated $1.9 billion in 2025 revenue at $465,000 per dose. NXC-201 targets a smaller market but faces zero CAR-T competition.

At 10% penetration of the US market (approximately 3,850 patients per year) and $400,000 per dose, peak sales approach $1.54 billion. That is 2.6x IMMX’s current $592 million market cap. A 20% penetration scenario reaches $3 billion, or 5x the current valuation. The comp framework is straightforward: biotech valuation methods apply a 4x peak sales multiple for late-stage assets, implying $6.2 billion in pipeline value at 10% penetration. The market is currently assigning the pipeline near-zero value relative to that framework.

The FDA path risk

The critical risk is whether the FDA accepts a single-arm Phase 2 trial as the basis for a BLA. The trial has a registrational design, Breakthrough Therapy Designation, and RMAT designation, all of which support an accelerated approval pathway. But the FDA could require a randomized confirmatory trial before BLA acceptance, which would push the timeline to 2028 and test IMMX’s cash position.

The company’s guidance is aggressive: BLA submission planned in 2026 after the top-line readout, with 1-year follow-up data expected by end of March 2027. If the FDA accepts the single-arm data, the approval could come in 2027. If the agency requires a randomized trial, the stock re-rates downward and the cash runway becomes the binding constraint.

Immix had approximately $100 million in cash as of December 2025, following a $150 million equity offering at $8.94 per share. The annual burn rate is approximately $25 million. The Q1 2026 net loss was $0.18 per share, beating the consensus estimate of $0.21. At the current burn rate, the $100 million provides roughly 4 years of runway, enough to reach a BLA filing even without additional raises. But a randomized confirmatory trial would cost significantly more and force dilution.

Competitive context

The competitive picture in AL amyloidosis is thin. Standard of care is daratumumab-based regimens and bortezomib combinations. No CAR-T or bispecific is approved for AL amyloidosis specifically. The CRISPR Therapeutics allogeneic CAR-T program targets oncology indications but not AL amyloidosis.

The closest comparable is the BCMA CAR-T class in multiple myeloma. Carvykti at $1.9 billion in revenue and Abecma at lower revenue demonstrate that BCMA CAR-T works commercially. But myeloma is a 10x larger market than AL amyloidosis. The question for IMMX is whether being first in a smaller market is worth more than being third in a larger one.

The registrational trial design literature suggests single-arm trials can support accelerated approval in rare diseases with high unmet need, particularly with Breakthrough Therapy Designation. The 95% CR rate, if it holds in the full 45-patient cohort, is a strong enough signal that the FDA may not require a randomized trial for accelerated approval. The clinical trial phases framework allows for single-arm registrational studies when the natural history is well understood and the response rate dramatically exceeds the expected baseline.

Risks

The first risk is data degradation. The 95% CR rate is from a 20-patient interim cohort. The full 45-patient readout could show a lower rate as less-stringently-selected patients enroll. A drop to 70 to 75% would still be clinically meaningful but would weaken the BLA case.

The second risk is the FDA requiring a randomized trial. Breakthrough Therapy Designation does not guarantee accelerated approval. The agency has become more cautious about single-arm CAR-T approvals since the Abecma precedent, where accelerated approval was granted but the confirmatory trial was required.

The third risk is durability. AL amyloidosis CAR-T data is still early. The company expects 1-year follow-up data by March 2027. If responses are not durable at 1 year, the clinical benefit claim weakens.

The fourth risk is micro-cap volatility. At $592 million market cap with 21 employees and low daily volume (1.59 million shares on July 31), the stock can move 20% on a single press release. The September 2026 update is the catalyst that determines whether this is a $1.5 billion company or a $300 million one.

Verdict

IMMX at $592 million is pricing NXC-201 at roughly $600 million in pipeline value after subtracting the $100 million in cash. For a therapy with a 95% CR rate, Breakthrough Therapy Designation, RMAT, and Orphan Drug Designation in an indication with zero approved CAR-Ts, that is a low price. The CAR-T cell therapy investing guide identified IMMX as the highest-risk, highest-reward entry in the cell therapy space, and that framing holds.

The September 2026 NEXICART-2 update is the binary event. If the full 45-patient cohort confirms a CR rate above 80% with clean safety, the stock re-rates toward $1 to $1.5 billion market cap as the BLA filing approaches. If the CR rate drops below 70% or the FDA signals a randomized trial requirement, the stock loses 30 to 50%.

Size this as a 1 to 2% position in a biotech portfolio ahead of the September update. The asymmetric payoff (2.5x upside on a positive readout, 50% downside on a miss) justifies the allocation. But this is a trade, not an investment. The thesis resolves at the data readout, and the position should be trimmed or exited based on the result.